IL Dong Pharmaceutical일동제약

IL Dong Pharmaceutical returned to profit on a trailing basis, but its share price has fallen sharply over the past year.

The company makes prescription and over-the-counter medicines, including the Aronamin vitamin range, and health supplements. Trailing twelve-month revenue to H1 2026 was about ₩582B with operating income of about ₩26B and net income of about ₩44B, after losses in 2021 to 2023. The shares closed at ₩12,570 on 2026-10-29, down 45.7% over one year and well below the 52-week high of ₩45,050.

What stands out

• Trailing net income of ₩44B is well above operating income of ₩26B, so the data does not show what drove the gap; the filings in this pack do not explain it.
• Operating margin improved to 4.4% trailing from 2.1% in 2024, after operating losses in 2021 to 2023, but revenue fell 7.8% in 2025.
• Balance sheet is leveraged: liabilities are 124.6% of equity and borrowings of ₩116B exceed cash of ₩53B.
• Valuation metrics are modest against peers: P/E of 9.1 and P/B of 1.5, with a 1.6% dividend yield.
• Foreign ownership fell from 10.5% to 5.9% over about 60 days, while foreign net flows over 20 days were positive and retail flows were negative.

What to watch

• The full-year 2026 earnings results, following the advance notice filed on 2026-10-28, which the data does not include in detail.
• The newly announced joint venture with Nine & Company in functional skincare and the share acquisition filed on 2026-09-30, including their financial effects, which the data does not detail.
• Debt levels and the gap between reported net income and operating income in upcoming filings.